论文部分内容阅读
异基因造血干细胞移植(allo-SCT)是治愈多种造血系统良恶性疾病及部分非血液系统疾病的重要手段之一。由于供体来源结构的变化,尤其是一胎化政策的影响,我国非血缘造血干细胞移植(URD-SCT)已成为allo-SCT的主体,且呈现稳定增长的态势。1非血缘移植的发展与现状1980年,首次报道了非血缘外周血干细胞移植治疗急
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is one of the important means to cure many kinds of hematopoietic malignancies and some non-hematological diseases. Due to the change of donor source structure, especially the influence of one-child policy, URD-SCT has become the main body of allo-SCT and has shown a steady growth trend. 1 The development and status of non-blood transplantation In 1980, for the first time reported non-blood-derived peripheral blood stem cell transplantation for acute treatment